TABLE 2.
PN treatment, mg·kg−¹·d−¹ | Tissue concentration, nmol/g | PL-to-PN concentration ratio2 | ||||||
---|---|---|---|---|---|---|---|---|
Tissue | PLP | PMP | PL | PN | PM | 4-PA | ||
Plasma3 | 7 | 588 (41) | 6.5 (1.3) | 685 (29) | 30.1 (4.4) | 16.5 (1.7) | 16.4 (6.1) | 22.76 |
1400 | 634 (52) | 9.1 (0.7)* | 4593 (269)*** | 1375.5 (308.33)*** | 38.2 (2.5)*** | 734.6 (92.8)*** | 3.34 | |
RBCs3 | 7 | 203 (10) | 104.1 (3.3) | 939 (76) | 2.1 (2.1) | 3.9 (2) | ND | 447.14 |
1400 | 947 (43)*** | 100.6 (9.1) | 21,502 (1186)*** | 47.1 (47.1) | 7 (5.2) | 13.8 (8.7) | 456.52 | |
Gastrocnemius4 | 7 | 14.9 (1.4) | 8.1 (0.5) | 0.12 (0.05) | 0.27 (0.07) | 0.49 (0.16) | ND | 0.44 |
1400 | 9.7 (0.8)*** | 6.9 (1.1)Ɨ | 2.47 (0.37)*** | 2.23 (0.77)ǂ | 0.8 (0.32) | ND | 1.11 | |
Brain | 7 | 7.57 (0.4) | 11.3 (0.5) | 1.06 (0.33) | 0.15 (0.05) | 0.11 (0.04) | 0.25 (0.1) | 7.07 |
1400 | 7.32 (1.29) | 10.2 (0.7) | 3.81 (0.39)*** | 0.2 (0.07) | 0.14 (0.02) | 0.38 (0.16) | 19.05 | |
Liver | 7 | 24.5 (1.9) | 25.1 (1.1) | 1 (0.3) | 0.31 (0.09) | 0.3 (0.17) | 0.92 (0.52) | 3.23 |
1400 | 24.4 (1.7) | 23.5 (0.8) | 2.6 (0.5)** | 0.38 (0.08) | 0.29 (0.14) | 0.71 (0.37) | 6.84 | |
Kidney | 7 | 9.3 (1.3) | 28.4 (0.8) | 3.7 (0.4) | 0.27 (0.12) | 13.9 (0.6) | ND | 13.7 |
1400 | 10 (1.0) | 28.1 (1.9) | 13.8 (1.9)*** | 7.66 (2.34)** | 14.9 (1.9) | ND | 1.8 |
Data were obtained from Schaeffer et al. (97). All values are means (SEM), n = 5–6, except for plasma and RBCs (SD), for which n = 11–12. *,**,***Different between diet groups within a tissue: *P < 0.11, **0.01 < P < 0.05, ***P < 0.01. ND, not detected; PL, pyridoxal; PLP, pyridoxal 5′-phosphate; PM, pyridoxamine; PMP, pyridoxamine 5′-phosphate; PN, pyridoxine; PNP, pyridoxine 5′-phosphate; 4-PA, 4-pyridoxic acid.
The concentration ratios of PL to PN were calculated using mean values.
Concentration values in plasma and RBCs are given in nmol/L.
Tissue concentrations are based on analysis of the right gastrocnemius only: ƗP = 0.1, ǂP = 0.06.